Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.17
ECTE's Cash to Debt is ranked lower than
89% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. ECTE: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
ECTE' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 24.88 Max: No Debt
Current: 0.17
F-Score: 3
Z-Score: -331.16
M-Score: -113.93
WACC vs ROIC
13.86%
-1105.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -1138.71
ECTE's ROE (%) is ranked lower than
100% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. ECTE: -1138.71 )
Ranked among companies with meaningful ROE (%) only.
ECTE' s ROE (%) Range Over the Past 10 Years
Min: -634.59  Med: -130.82 Max: -54.38
Current: -1138.71
-634.59
-54.38
ROA (%) -409.98
ECTE's ROA (%) is ranked lower than
99% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. ECTE: -409.98 )
Ranked among companies with meaningful ROA (%) only.
ECTE' s ROA (%) Range Over the Past 10 Years
Min: -331.29  Med: -93.30 Max: -35.73
Current: -409.98
-331.29
-35.73
ROC (Joel Greenblatt) (%) -2699.48
ECTE's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 757 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.44 vs. ECTE: -2699.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ECTE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7978.26  Med: -4312.95 Max: -967.71
Current: -2699.48
-7978.26
-967.71
Revenue Growth (3Y)(%) -100.00
ECTE's Revenue Growth (3Y)(%) is ranked lower than
99% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. ECTE: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ECTE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -88.10 Max: 44.2
Current: -100
0
44.2
EBITDA Growth (3Y)(%) -13.30
ECTE's EBITDA Growth (3Y)(%) is ranked lower than
80% of the 545 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. ECTE: -13.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ECTE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.4  Med: -26.40 Max: 14.6
Current: -13.3
-53.4
14.6
EPS Growth (3Y)(%) -14.10
ECTE's EPS Growth (3Y)(%) is ranked lower than
77% of the 501 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. ECTE: -14.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ECTE' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.2  Med: -28.20 Max: 1603.1
Current: -14.1
-49.2
1603.1
» ECTE's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-15)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ECTE Guru Trades in Q4 2014

Jim Simons 22,400 sh (+121.78%)
» More
Q1 2015

ECTE Guru Trades in Q1 2015

Charles Brandes 34,000 sh (New)
Jim Simons 16,600 sh (-25.89%)
» More
Q2 2015

ECTE Guru Trades in Q2 2015

Charles Brandes 34,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2015

ECTE Guru Trades in Q3 2015

Charles Brandes Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ECTE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Current Ratio 0.09
ECTE's Current Ratio is ranked lower than
100% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. ECTE: 0.09 )
Ranked among companies with meaningful Current Ratio only.
ECTE' s Current Ratio Range Over the Past 10 Years
Min: 0.08  Med: 1.08 Max: 10.69
Current: 0.09
0.08
10.69
Quick Ratio 0.09
ECTE's Quick Ratio is ranked lower than
100% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. ECTE: 0.09 )
Ranked among companies with meaningful Quick Ratio only.
ECTE' s Quick Ratio Range Over the Past 10 Years
Min: 0.08  Med: 1.08 Max: 10.69
Current: 0.09
0.08
10.69

Valuation & Return

vs
industry
vs
history
Price/Graham Number 0.37
ECTE's Price/Graham Number is ranked higher than
95% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. ECTE: 0.37 )
Ranked among companies with meaningful Price/Graham Number only.
ECTE' s Price/Graham Number Range Over the Past 10 Years
Min: 0.08  Med: 1.46 Max: 5.1
Current: 0.37
0.08
5.1
Earnings Yield (Greenblatt) (%) -121.51
ECTE's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. ECTE: -121.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ECTE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -121.51  Med: 3.50 Max: 5.3
Current: -121.51
-121.51
5.3

More Statistics

Revenue(Mil) $0
EPS $ -1.97
Beta1.61
Short Percentage of Float2.78%
52-Week Range $0.88 - 2.40
Shares Outstanding(Mil)11.12

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NAS:TNXP, XKRX:118000, BOM:509079, XKRX:000520, XLJU:SALR, ASX:NRT » details
Traded in other countries:XS5B.Germany,
Echo Therapeutics Inc was incorporated in Delaware in September 2007 under the name Durham Pharmaceuticals Acquisition Co. It is a medical device company with expertise in skin permeation technology. The Companys medical device program is Symphony, a non-invasive, wireless, continuous glucose monitoring system designed to provide reliable, real-time glucose data conveniently, continuously and cost-effectively. The Symphony CGM System incorporates its SkinPrep device, transdermal glucose sensor, wireless transmitter and data display monitor. It is developing its Prelude SkinPrep System as a platform technology to allow for enhanced skin permeation that will enable two important applications; analyte extraction and needle-free drug delivery. It currently has two key strategic partnerships in place. It has granted Ferndale Pharma Group, Inc. a license to develop, market and sell the Prelude device for enhanced and needle-free delivery of topical anesthetics prior to needle insertion. It has also granted Handok Pharmaceuticals Co., Ltd. a license to develop, market and sell the Symphony CGM System for continuous glucose monitoring in South Korea. The Company competes with Edwards Lifesciences Corporation, Optiscan Biomedical Corp., Maquet Critical Care AB, Medtronic, Inc. A. Menarini Diagnostics S.r.l., Roche, Johnson & Johnson, Bayer and Abbott Laboratories. Government authorities in the United States, at the federal, state and local level, the European Union, and other countries extensively regulate the research, development, testing, manufacture, labeling, promotion, advertising, distribution, marketing, export and import of products such as those the Company are developing.
» More Articles for ECTE

Headlines

Articles On GuruFocus.com
5 Healthcare Picks for 2012 Mar 21 2012 

More From Other Websites
Echo Therapeutics Announces Conference Call to Provide an Update on Corporate Milestones Apr 28 2016
Echo Therapeutics Announces Conference Call to Provide an Update on Corporate Milestones Apr 28 2016
Echo Therapeutics Announces Voting Results of Special Meeting of Stockholders Apr 26 2016
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Apr 19 2016
Echo Therapeutics Announces Voting Results of Special Meeting of Stockholders Apr 14 2016
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Apr 14 2016
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Apr 06 2016
ECHO THERAPEUTICS, INC. Financials Apr 06 2016
Echo Therapeutics, Inc. Announces 2015 Financial Results Mar 31 2016
Echo Therapeutics, Inc. Announces 2015 Financial Results Mar 30 2016
ECHO THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Mar 30 2016
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Mar 22 2016
Echo Therapeutics Says Nasdaq Granted Request to Remain Listed Mar 10 2016
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Mar 10 2016
Echo Therapeutics Announces New Patents for Non-Invasive Sensing Technology Feb 22 2016
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Feb 12 2016
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Feb 10 2016
Echo Therapeutics Announces Conference Call and Webcast to Provide a Corporate Update Feb 08 2016
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Feb 03 2016
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Feb 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK